Someone else's clock has started running against them: the company is being paid to solve a problem that is already cost
The model's full reasoning — Q1 2018 call → NOWe need answer only YES or NO. Need analyze transcript. Question: Does management describe that its counterparties are already losing something real and ongoing for as long as they do not have what company provides, and that this accumulating loss is already visible in how those parties are behaving toward company today? Need both halves: running meter on other side, and other side already acting like meter running. Also meaningful relative to company size and contribution ahead. We need use only transcript. Company Ascendis Pharma rare disease endocrinology pipeline. Products: TransCon Growth Hormone, TransCon PTH, TransCon CNP. Focus on unmet medical need. For hypoparathyroidism: patients suffer symptoms despite current therapies. Short-term symptoms, long-term complications, increased risk renal disease, economic burden: 79% require hospital stays or ER visits, 85% unable perform household duties, 20% employment change. This describes counterparties (patients) currently suffering/losing due to lack of treatment. Is that a running meter? They are patients with disease, ongoing burden. But is it "as long as they do not have what company provides"? Yes, current therapies inadequate. Are they already acting like meter running? Need evidence in behavior toward company: "We have three product candidates in clinical development" etc. But for PTH, company planning Phase 3, not yet marketed. Patients not acting as paying customers. Trials enrolling? For growth hormone, fliGHt actively enrolling, "response indicates interest on part of patients and investigators to switch from daily to weekly growth hormone." That is behavior. But is it losing something real ongoing? Patients on daily GH have burden? Need identify counterparty. Could be patients with growth hormone deficiency? Current daily injections. Company offers weekly. But is delay expensive? Not described as accumulating loss; more convenience. For hypoparathyroidism, current therapies inadequate leading to severe symptoms. That is ongoing loss. But behavior? Not yet because product in development. Maybe "we have completed Phase 1" etc. No customers pressing. The question specifically asks "counterparties are already losing something real and ongoing ...
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
SYM · Q3 2022 → YESThe question is: Does management describe that ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING — money, output, access, standing, time, or an opportunity of their own — FOR AS LONG AS...YES The transcript shows management describing customers' ongoing pain from labor shortages and broken supply chains that prevent them from handling demand, with customers actively clamoring for faster deployments and wanting the system as quickly as possible.
CRL · Q2 2022 → YESThe question is whether management describes that their counterparties are already losing something real and ongoing — money, output, access, standing, time, or an opportunity — for as long as they do...
GTES · Q4 2021 → YESThe question is: Does management describe that ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING — money, output, access, standing, time, or an opportunity of their own — FOR AS LONG AS...